Trial Profile

A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Programmed Death Ligand 1-Positive Non Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belrestotug (Primary) ; Dostarlimab (Primary) ; Nelistotug (Primary) ; Pembrolizumab
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms GALAXIES LUNG-201
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

13 May 2025 Status changed from recruiting to discontinued.as per iTeos media release.
13 May 2025 Topline results from an updated interim analysis presented in the iTeos Therapeutics Media Release.
10 Jan 2025 According to an iTeos Therapeutics Inc media release, topline data anticipated in 2Q25.Data are expected to be submitted for presentation at a scientific congress in 2H 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com